Promising Developments and Strong Financials Support Buy Rating for Dianthus Therapeutics

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Dianthus Therapeutics (DNTH – Research Report). The associated price target remains the same with $40.00.

Swayampakula Ramakanth’s rating is based on several promising developments at Dianthus Therapeutics. The company is set to release topline data from its Phase 2 MaGic study in September, which will provide insights into the effectiveness of their C1s inhibitor, DNTH103, for treating anti-AChR+ generalized Myasthenia Gravis (gMG). This study is significant as it compares DNTH103 against existing C5 inhibitors, which have boxed warnings. The expectation is that DNTH103 will demonstrate a favorable safety profile and notable efficacy, potentially positioning it as a best-in-class treatment option due to its self-administered, subcutaneous dosing.
Additionally, Dianthus is progressing with its Phase 3 CAPTIVATE study for chronic inflammatory demyelinating polyneuropathy (CIDP) and the Phase 2 MoMeNtum study for Multifocal Motor Neuropathy (MMN), with data expected in the second half of 2026. These studies could further validate DNTH103’s therapeutic potential. Financially, the company reported better-than-expected license revenue and maintains a strong cash position, which is anticipated to support operations into the second half of 2027. These factors collectively underpin Ramakanth’s Buy rating for Dianthus Therapeutics.